Target type: biologicalprocess
A process that modulates the formation of a microvillus. [GOC:mah]
Microvillus assembly, a critical process for epithelial cell function, is meticulously regulated by a complex interplay of signaling pathways, cytoskeletal dynamics, and protein interactions. This intricate process involves the coordinated recruitment and assembly of various proteins, including actin, myosin, and various transmembrane and scaffolding proteins, to the apical surface of epithelial cells, ultimately forming finger-like protrusions known as microvilli. Regulation of microvillus assembly is initiated by signaling pathways, such as the Wnt, Rho, and MAPK pathways, which respond to external stimuli and trigger intracellular signaling cascades that activate downstream effectors. These effectors, including Rho GTPases, act as molecular switches, modulating the activity of key regulatory proteins involved in actin polymerization and cytoskeletal reorganization. One prominent example is the Rho GTPase Rac, which promotes the formation of branched actin filaments, a critical component of microvilli. The coordinated interplay of actin-binding proteins, such as villin, fimbrin, and ezrin, plays a crucial role in the assembly of the microvillus cytoskeleton. Villin, a calcium-sensitive actin-bundling protein, promotes the formation of tightly packed actin filaments, while fimbrin acts as a cross-linking protein that stabilizes the actin bundles. Ezrin, a member of the ERM protein family, connects the actin cytoskeleton to the plasma membrane, anchoring the microvillus to the cell surface. Beyond the cytoskeletal components, transmembrane proteins, such as the apical junctional complex proteins, play a crucial role in microvillus assembly. These proteins, including claudins, occludins, and junctional adhesion molecules (JAMs), contribute to the formation of tight junctions that seal the apical space and provide structural integrity to the epithelial barrier. The regulation of microvillus assembly is a dynamic and intricate process that requires the precise coordination of numerous cellular factors. Understanding the molecular mechanisms underlying this process is essential for comprehending epithelial cell function and for developing therapeutic strategies for diseases associated with defects in microvillus formation.'
"
Protein | Definition | Taxonomy |
---|---|---|
Fascin | A fascin that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16658] | Homo sapiens (human) |
Phospholipase D1 | A phospholipase D1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13393] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1-NA-PP1 | pyrazolopyrimidine | tyrosine kinase inhibitor | |
raloxifene | raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively. | 1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols | bone density conservation agent; estrogen antagonist; estrogen receptor modulator |
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | stilbenoid | ||
halopemide | halopemide: structure | ||
1-(4-pyridyl)piperazine | 1-(4-pyridyl)piperazine: structure in first source | ||
1-(2-pyridinyl)piperazine | 1-(2-pyridinyl)piperazine: metabolite of buspirone & gepirone | ||
afimoxifene | afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. | phenols; tertiary amino compound | antineoplastic agent; estrogen receptor antagonist; metabolite |
sch-202676 | SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors; structure in first source | ||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
5-fluoro-2-indolyldeschlorohalopemide | benzimidazoles | ||
N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide | naphthalenecarboxamide | ||
vu0155069 | |||
ml298 | |||
ml299 | ML299: has antineoplastic activity; structure in first source |